Health related quality of life in the Nordic randomized trial of adjuvant intermediate-dose interferon α-2b in high-risk melanoma

被引：0
|
作者：
Brandberg, Yvonne [1 ]
Aamdal, Steinar [2 ]
Bastholt, Lars [3 ]
Hernberg, Micaela [4 ]
Stierner, Ulrika [5 ]
von der Maase, Hans [6 ]
Hansson, Johan [1 ]
机构：
[1] Karolinska Inst, Dept Oncolog Pathol, Stockholm, Sweden
[2] Norwegian Radium Hosp, Dept Clin Canc Res, Oslo, Norway
[3] Odense Univ Hosp, Inst Clin Res, DK-5000 Odense, Denmark
[4] Univ Helsinki, Dept Oncol, Helsinki, Finland
[5] Gothenburg Univ, Sahlgrenska Acad, Dept Oncol, S-41124 Gothenburg, Sweden
[6] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
来源：
PIGMENT CELL & MELANOMA RESEARCH | 2008年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：278 / 278
页数：1
相关论文
共 50 条
  • [1] Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma.
    Hansson, J.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Nilsson, B.
    Stierner, U. K.
    von der Maase, H.
    Brandberg, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
    Brandberg, Y.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Stierner, U.
    von der Maase, H.
    Hansson, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (13) : 2012 - 2019
  • [3] Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma
    Hansson, J.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Nilsson, B.
    Stierner, U.
    von der Maase, H.
    [J]. EJC SUPPLEMENTS, 2007, 5 (06): : 4 - 4
  • [4] Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
    Hansson, Johan
    Aamdal, Steinar
    Bastholt, Lars
    Brandberg, Yvonne
    Hernberg, Micaela
    Nilsson, Bo
    Stierner, Ulrika
    von der Maase, Hans
    [J]. LANCET ONCOLOGY, 2011, 12 (02): : 144 - 152
  • [5] The feasibility of adjuvant interferon α-2b in children with high-risk melanoma
    Navid, F
    Furman, WL
    Fleming, M
    Rao, BN
    Kovach, S
    Billups, CA
    Cain, AM
    Amonette, R
    Jenkins, JJ
    Pappo, AS
    [J]. CANCER, 2005, 103 (04) : 780 - 787
  • [6] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [7] Feasibility of high-dose interferon-α2b adjuvant therapy for high-risk resected cutaneous melanoma
    Muggiano, A
    Mulas, C
    Fiori, B
    Liciardi, G
    Pintus, M
    Tanca, L
    Tedde, A
    Turno, R
    Desogus, A
    [J]. MELANOMA RESEARCH, 2004, 14 (02) : S1 - S7
  • [8] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [9] INTERMEDIATE DOSE INTERFERON ALFA 2B (IFN ALFA 2B) IN ADJUVANT TREATMENT OF MALIGNANT MELANOMA
    Calabria, Caterina
    Savio, Giuseppina
    Laudani, Agata
    Leonardi, Vita
    Blasi, Livio
    Stefano, Rosalba
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 88 - 89
  • [10] Health-related quality of life measures in melanoma patients receiving pulsed high-dose intravenous interferon alpha 2b (IFNα2b)
    Mohr, P.
    Hauschild, A.
    Trefzer, U.
    Neuber, K.
    Enk, A.
    Raas, K.
    Gogas, H.
    Kuechler, T.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345